FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as ... has approvals in cardiovascular disease and chronic kidney disease and is looking at various other indications ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Eli Lilly and Novo Nordisk have been competing ... including chronic kidney disease. Similarly, tirzepatide has been approved for type 2 diabetes under the name Mounjaro and for obesity under ...

Eli Lilly & Co. (NYSE ... weight loss in its SURMOUNT-5 trials. Tirzepatide was also approved on Dec 20, 2024, for obstructive sleep apnea and is being studied for additional indications, which ...

#Eli_Lilly's #Zepbound ... obstructive sleep apnea. Tirzepatide is being investigated for four additional indications, including cardiovascular risk factors, chronic kidney disease, and metabolic ...